Refine by
Influenza A Virus Articles & Analysis
21 news found
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its innovative Influenza A Virus Mouse Models to assess the impact of virus-host interactions. ...
Influenza A virus is a genus of virus in the family Orthomyxoviridae and causes influenza in birds and some mammals. Influenza A virus strains of all subtypes have been isolated from wild birds, but disease is rare. ...
Infectious Diseases: Antibodies are developed against rapidly evolving pathogens, such as the influenza virus and SARS-CoV-2. In addition to Antibody De Novo Design, CD ComputaBio's platform extends its capabilities to Protein Drug Design, enabling the creation of highly efficient and specific small molecule drugs. ...
Meanwhile, it is critical to keep the virus concentration low so as to detect infection and not saturate antibodies in the serum. ...
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. ...
Neuraminidase (NA), also known as sialidase, is a glycoprotein distributed on the envelope of the influenza virus. It is antigenic and can catalyze the hydrolysis of sialic acids, helping mature influenza viruses detach from host cells and infect new cells. ...
David and his lab have specialized in research on influenza viruses for several years, they obtain very fruitful findings to be shared in the webinar. ...
The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections and diseases caused by six common devastating viruses – adenovirus (AdV), BK ...
ByKalaris
Many RNA viruses need to activate this pathway to ensure their replication, such as influenza viruses[xii], hantaviruses[xiii], or the respiratory syncytial virus (RSV)[xiii] , and also coronaviruses[xiii] , including SARS-CoV-2. Zapnometinib inhibits the cellular MEK (MAPK/ERK kinase), blocking the formation of functional virus particles in the ...
This study is the second Phase 3 registrational study of posoleucel, following the initiation of the Phase 3 study for the treatment of virus-associated HC last year. Separately, the company also announced the initiation of a Phase 1/2 clinical trial (NCT04933968) of ALVR106, its investigational, allogeneic, off-the-shelf, multi-VST therapy for the treatment of infections caused ...
ByKalaris
Martinez-Sobrido, PhD, professor in the Department Disease Intervention & Prevention at Texas Biomed is widely recognized in the development of recombinant viruses, specifically influenza, arenaviruses, and Zika virus, using plasmid-based reverse genetic approaches. ...
EnGen Bio is an early stage biotechnology company developing a new approach to preventing and treating all Type A influenza strains—including all flu pandemics. Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global ...
Seasonal flu causes 50,000–250,000 deaths worldwide annually, causing the World Health Organization to declare the development of a universal flu vaccine as an urgent need in its Global Influenza Strategy (2019–2030) report. The unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on ...
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or ...
Hence, polyclonal antibodies are better adapted to potential changes the antigen may undergo, e.g., after a virus mutation. Using an antigen derived from SARS-CoV-2, the company has launched a development programme for polyclonal antibodies F(ab’)2 to be administered by injection to hospital inpatients, in order to generate passive immunity in these patients. These ...
SaNOtize also announced that new tests conducted by the Institute for Antiviral Research at Utah State University confirm SaNOtize’s Nitric Oxide Releasing Solution (NORSTM) inactivated more than 99.9% of SARs-CoV-2, the virus that causes COVID-19, within two minutes, in laboratory tests. ...
The patents based on WO2015/063085 cover a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein and forms the basis of the company’s technology platform. ...
To achieve this, it will develop a candidate vaccine comprising a recombinant, proprietary, and highly immunogenic version of the influenza virus nucleoprotein (NP). The candidate vaccine from the OPTIVAC project will be administered in conjunction with current influenza vaccines with the aim of improving their efficacy, particularly in the ...
Because asthma was the most common underlying health condition among those hospitalized in the United States with 2009 H1N1 influenza infection during the 2009-2010 influenza season, NHLBI and NIAID conducted a collaborative study to establish safe and effective strategies to vaccinate children and adults with mild to severe asthma against the 2009 pandemic H1N1 ...
Because asthma was the most common underlying health condition among those hospitalized in the United States with 2009 H1N1 influenza infection during the 2009-2010 influenza season, NHLBI and NIAID conducted a collaborative study to establish safe and effective strategies to vaccinate children and adults with mild to severe asthma against the 2009 pandemic H1N1 ...